QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ef-hutton-maintains-buy-on-hoth-therapeutics-maintains-5-price-target

EF Hutton analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

 hoth-therapeutics-received-institutional-review-board-approval-from-the-montefiore-medical-center-and-the-dana-farber-cancer-institute-to-proceed-with-its-first-in-human-phase-2a-clinical-trial-of-ht-001-for-the-treatment-of-skin-toxicities-associated-with-epidermal-growth-factor-receptor-inhibitors

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical TrialNEW YORK, Sept. 5, ...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

Core News & Articles
Market-Moving News for July 24th
07/24/2024 12:34:15

TSLA: -8.8% | Tesla shares are trading lower following mixed Q2 earnings. The company also said it expects 2024 vehicle volume ...

 hc-wainwright--co-reiterates-buy-on-hoth-therapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...

 hoth-therapeutics-approved-to-proceed-with-first-in-human-phase-2a-clinical-trial-of-ht-001-for-treatment-of-skin-toxicities-associated-with-epidermal-growth-factor-receptor-inhibitors

Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION